News

Around 600 patients are expected be enrolled in the study and will be randomized with PB272 plus Xeloda or Tykerb plus Xeloda. Puma Biotechnology chief executive officer and

Pharmavite chief operating officer Mark Walsh said, "At 330,000 square feet, the Opelika-based Pharmavite facility is one of the largest vitamin, mineral and supplement (VMS) manufacturing facilities built

Conducted in 56 patients with hypercholesterolemia and a history of intolerance to two or more statins, the study demonstrated considerable tolerability profile of the investigational candidate. Following an

Indicated for people with body mass index (BMI) of 30kg/m2 or more, or BMI of 27kg/m2 or more and coupled with a minimum of one weight-related medical condition

The investigational product is an oral nucleotide analogue inhibitor to be administered once each day with the safety and efficacy profile yet to be evaluated. Under the Prescription

Designed to lessen attrition rates and improve the ranking of early drug candidates, the new system comprises both manufacturability and safety assessments for early detection of possible chemical/physical

The collaboration will leverage CytomX’s Probody Platform to develop safe and effective antibody-drug conjugates (ADCs). CytomX chief executive officer Sean McCarthy said, "Combining our novel Probody Platform with

Backed by PA Consulting-developed social media analysis software, the patient recruitment program will enable users’ to access new information about potential patients, including mapping the geographical distribution of

AB SCIEX Triple Quad 6500 LC-MS/MS Systems are designed to facilitate higher levels of sensitivity and increased limits of quantitation to its bioanalytical services in support of pharmacokinetic